Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methoxy polyethylene glycol-epoetin beta (Chugai Pharmaceutical Co., Ltd.)
- Development stage
- Approved
- Lead developer
- Chugai Pharmaceutical Co., Ltd.
- Modality
- Recombinant Proteins and Enzymes
- Administration
- intravenous, subcutaneous
01
Overview
Methoxy polyethylene glycol-epoetin beta (sold under the brand name Mircera) is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anemia associated with chronic kidney disease (CKD) in adult and pediatric patients. It is a chemically modified erythropoiesis-stimulating agent (ESA) created by covalently linking epoetin beta with a linear methoxy polyethylene glycol (PEG) molecule. This modification significantly extends its serum half-life (approximately 134 hours) compared to conventional epoetins, allowing for less frequent administration (once every two weeks or once monthly). It stimulates erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow.
- Brand names
- Mircera
- Other names
- C.E.R.A.CERAcontinuous erythropoietin receptor activatormethoxy polyethylene glycol-epoetin betamethoxy-polyethylene glycol-epoetin betapeg-epoetin betapegserepoetin alfapegzerepoetin alfa
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on methoxy polyethylene glycol-epoetin beta (Chugai Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methoxy polyethylene glycol-epoetin beta (Chugai Pharmaceutical Co., Ltd.).